secwatch.observer — SEC 8-K summary
======================================

Issuer:     Context Therapeutics Inc. (CNTX)
CIK:        0001842952
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0001842952-24-000022
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Context Therapeutics submits IND for CTIM-76 Phase 1 trial in CLDN6-positive cancers
--------------------------------------------------------------------------------

- IND filed March 28, 2024 with FDA for CTIM-76, a CLDN6 x CD3 bispecific antibody.
- Phase 1 dose escalation/expansion trial planned in CLDN6-positive gynecologic and testicular cancers.
- CEO Martin Lehr calls IND submission a significant milestone for the company.
- Company set aggressive 2021 timeline and prioritized CTIM-76 as potentially best-in-class therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842952/000184295224000022/0001842952-24-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842952/000184295224000022/cntx-20240401.htm
  HTML page:      https://secwatch.observer/filing/0001842952-24-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer